Stock of the Day for July 11, 2025

BeOne Medicines Stock Report

BeOne Medicines
ONC 90-day performance NASDAQ:ONC BeOne Medicines
Current Price
$306.05
+8.09 (+2.72%)
(As of 04:00 PM ET)
30 Day Performance
2.04%
  
 
90 Day Performance
24.39%
  
 
Market Capitalization
$33.54B
Price Target
$330.89
Net Income
-$644.79M

About BeOne Medicines

BeOne Medicines is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation cancer immunotherapies. The company’s core focus lies in engineering T-cell engager antibodies designed to recruit and activate a patient’s own immune system against solid tumors. By leveraging a proprietary platform for bispecific antibody design, BeOne Medicines aims to create therapies with enhanced specificity and safety profiles compared with conventional approaches.

The company’s pipeline comprises multiple early-stage programs directed at validated tumor-associated antigens. These candidates are advancing through preclinical studies, with plans to initiate first-in-human trials in the near term. BeOne Medicines applies a rational target selection process and modular antibody format to optimize pharmacokinetics and tumor penetration, seeking to address unmet needs in indications that have shown limited response to existing treatments.

Guided by a multidisciplinary management team with extensive experience in oncology drug development, BeOne Medicines collaborates with leading academic institutions and contract research organizations to accelerate its programs. The company maintains strategic partnerships to support process development, manufacturing, and regulatory strategy, positioning it to progress its immuno-oncology candidates toward clinical milestones and potential commercialization.

ONC Company Calendar

AUG. 6, 2025
Last Earnings
AUG. 29, 2025
Today
DEC. 31, 2025
Fiscal Year End

Recent BeOne Medicines News

BeOne Medicines announces EC approved Tevimbra to treat NSCLC
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
This report was written by MarketBeat.com on July 11, 2025 and updated on August 29, 2025. This report first appeared on MarketBeat.com.